Adipotide (FTPP) Research: Targeted Proapoptotic Peptide and White Adipose Vascular Biology

Adipotide (FTPP — Fat-Targeted Proapoptotic Peptide) is a synthetic chimeric research peptide designed to selectively induce apoptosis in the blood vessel endothelium supplying white adipose tissue. It represents a class of research tools called targeted proapoptotic peptides, combining a tissue-specific homing domain with a cell-killing proapoptotic sequence.

Chimeric Design: Two Functional Domains

Adipotide's CKGGRAKDC-GG-KLAKLAKKLAKLAK sequence has two distinct functional regions separated by a flexible GG linker:

Homing domain: CKGGRAKDC. This 9-residue sequence was identified by Kolonin et al. (Nature Medicine, 2004) through in vivo phage display screening — injecting a library of phage expressing different peptide sequences into mice and recovering those that accumulated selectively in white adipose tissue vasculature. The CKGGRAKDC sequence was consistently enriched in white adipose tissue blood vessels versus other vascular beds, establishing it as a WAT-selective vascular homing peptide.

Proapoptotic domain: KLAKLAKKLAKLAK. The KLAKLAK sequence was originally developed as a synthetic antimicrobial peptide that disrupts cell membranes. When targeted to mitochondria, it disrupts the inner mitochondrial membrane, triggering the intrinsic apoptosis pathway. Crucially, the KLAKLAK domain in Adipotide uses all D-amino acids — making it completely resistant to proteolytic degradation while preserving the membrane-disrupting amphipathic alpha-helical structure.

Prohibitin: The Molecular Target

Barnhart et al. (Cell Metabolism, 2011) published the identification of prohibitin as the molecular target of the CKGGRAKDC homing peptide on white adipose tissue vasculature. Prohibitin is normally an inner mitochondrial membrane protein with roles in mitochondrial chaperone function, but it is overexpressed on the luminal surface of white adipose tissue blood vessels — an unusual extracellular localisation that creates the target for CKGGRAKDC binding.

This surface prohibitin overexpression on WAT endothelium versus other vascular beds provides the selectivity that makes Adipotide a white adipose tissue-specific research tool. The mechanism by which prohibitin reaches the extracellular surface in WAT endothelium, and why it is specifically upregulated there, are active areas of vascular biology research.

Research Applications

White adipose tissue vascular biology. The central research question enabled by Adipotide: what happens to tissue function when its vascular supply undergoes selective apoptosis? Published primate research examined adipose tissue mass changes following Adipotide treatment, providing a model for studying adipose vascular-stromal interdependence.

Prohibitin receptor pharmacology. Adipotide can be used to characterise prohibitin binding kinetics, CKGGRAKDC-prohibitin interaction specificity, and competitive displacement of other prohibitin-binding molecules in cell-based assays.

Targeted proapoptotic peptide mechanism research. Adipotide serves as a model system for understanding how dual-domain chimeric peptides — combining a targeting domain with a cytotoxic domain — can achieve tissue specificity. The CKGGRAKDC-KLAKLAK design has been used as a template for developing analogous targeting peptides for other tissue types.

Comparative adipose biology. Research comparing white adipose tissue vascular depletion (via Adipotide) with pharmacological adipogenesis inhibition (via other tools) allows mechanistic dissection of the contribution of adipose vasculature versus adipocyte biology to tissue-level phenotypes.

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use.

Related: IGF-1 LR3 | AICAR
View Adipotide (FTPP) product and buy →

Prohibitin Biology: Normally Mitochondrial, Aberrantly Vascular

Prohibitin's normal function is as an inner mitochondrial membrane protein involved in mitochondrial chaperone activity, membrane protein quality control, and respiratory chain assembly. PHB1 (prohibitin 1) and PHB2 (prohibitin 2) form large, ring-like oligomeric complexes embedded in the inner mitochondrial membrane, where they stabilise newly imported respiratory chain subunits and prevent premature aggregation.

The discovery that prohibitin is overexpressed on the luminal surface of white adipose tissue blood vessel endothelium represents an unusual biology. Prohibitin surface expression on cells — where it is accessible to extracellular ligands like CKGGRAKDC — implies membrane translocation from its normal inner mitochondrial location to the plasma membrane. The mechanism of this translocation and why it occurs specifically in WAT vasculature (but not in most other vascular beds) remains incompletely characterised and represents active research frontier for Adipotide biology.

Published research by Barnhart et al. (Cell Metabolism, 2011) established prohibitin as the Adipotide target through photoaffinity crosslinking (using a photoactivatable CKGGRAKDC derivative to covalently capture interacting proteins, followed by mass spectrometry identification) and by showing that shRNA knockdown of prohibitin in endothelial cells reduced CKGGRAKDC binding. These experiments established prohibitin as the primary CKGGRAKDC receptor but did not fully explain why prohibitin appears on the cell surface of WAT endothelium specifically.

Proapoptotic Peptide Design: KLAKLAK Domain

The KLAKLAK domain is a well-established proapoptotic research tool independent of the Adipotide context. As a cell-penetrating, membrane-disrupting all-D-amino acid sequence, KLAKLAK has been conjugated to multiple targeting domains for cancer biology research — targeting tumour vasculature, cancer cells overexpressing specific surface markers, and other cell populations accessible to the targeting domain. Adipotide's CKGGRAKDC-KLAKLAK design was one of the earlier implementations of this targeted proapoptotic peptide (TAP) concept.

The D-KLAKLAK sequence (using all D-amino acids) is completely resistant to intracellular protease activity — this protease resistance is why KLAKLAK must use D-amino acids rather than L-amino acids. L-KLAKLAK is rapidly degraded intracellularly before it can reach mitochondria. D-KLAKLAK survives intracellular transit and inserts into the inner mitochondrial membrane, disrupting the membrane potential and triggering cytochrome c release and caspase cascade activation.

Frequently Asked Questions

What controls are essential for Adipotide research in white adipose tissue models?
Critical controls include: scrambled CKGGRAKDC sequence control (to confirm that CKGGRAKDC binding is sequence-specific rather than non-specific electrostatic interaction with the cell surface); KLAKLAK without the homing domain (to confirm that proapoptotic activity requires targeting rather than non-specific membrane disruption at research concentrations); shRNA prohibitin knockdown cells (to confirm prohibitin dependence of CKGGRAKDC binding); and fluorescently labelled Adipotide (to confirm cellular internalisation preceding apoptosis induction).

What primary cell types are most appropriate for Adipotide research?
Published Adipotide research has primarily used: primary human adipose microvascular endothelial cells (hAMECs) isolated from adipose tissue biopsies — these cells retain the WAT endothelial characteristics including surface prohibitin expression; human umbilical vein endothelial cells (HUVECs) as a non-adipose endothelial comparison (lower surface prohibitin, lower CKGGRAKDC binding); and 3T3-L1 differentiated adipocytes as the adipocyte compartment target in explant models. Comparing Adipotide binding and proapoptotic effects in WAT endothelial cells versus non-WAT endothelium (HUVECs, dermal microvascular ECs) characterises the tissue selectivity that makes Adipotide a WAT-specific research tool.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide

Adipotide Research: Concentration and Dose Selection

Published Adipotide research provides concentration reference data for both in vitro and in vivo research designs:

In vitro endothelial cell research: Published studies examining CKGGRAKDC binding to adipose endothelial cells have used fluorescently labelled CKGGRAKDC peptide at 1-10 microM for binding visualisation by confocal microscopy. For functional proapoptotic studies with full Adipotide in adipose endothelial cell monocultures, concentrations of 0.1-10 microM have been used, with apoptosis typically detectable by annexin V/PI staining at 1-5 microM after 24-48 hour incubation.

Selectivity controls: At concentrations above 10 microM, Adipotide may show non-specific cytotoxicity in non-adipose endothelial cells — the selectivity window for WAT endothelium over other cell types is best characterised at 0.1-5 microM. Always include non-adipose endothelial cells (HUVECs, dermal microvascular ECs) as selectivity controls at matched concentrations.

Published in vivo reference: Kolonin et al. (Nature Medicine, 2004) used approximately 1 mg/kg/day in mouse models for the initial characterisation. Barnhart et al. (Science Translational Medicine, 2011) used 1 mg/kg/day in non-human primate models. These published concentrations provide a framework for designing in vivo research studies, with the caveat that interspecies pharmacokinetic differences require appropriate dose adjustment for different model organisms.